For­ma sees da­ta 'sup­port­ing' sick­le cell ther­a­py dos­ing lev­els; Lian­Bio teams with Tar­sus for eye ir­ri­ta­tion in Chi­na

Look­ing to make a splash in sick­le cell, For­ma Ther­a­peu­tics pre­sent­ed new da­ta they hope can im­prove their shot at an even­tu­al FDA OK.

As part of an on­go­ing Phase I study, For­ma said its FT-4202 pro­gram showed enough he­mo­glo­bin in­creas­es to sup­port the dos­es se­lect­ed in the up­com­ing Phase II/III tri­al, which is cur­rent­ly en­rolling. Da­ta from two co­horts il­lus­trat­ed 10 of 14 pa­tients tak­ing the once-dai­ly ther­a­py saw a he­mo­glo­bin in­crease of at least 1 g/dL from base­line over the two-week treat­ment pe­ri­od.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.